Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Expenses: 2012-2025

Historic Operating Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $33.5 million.

  • Enanta Pharmaceuticals' Operating Expenses fell 24.63% to $33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.7 million, marking a year-over-year decrease of 20.42%. This contributed to the annual value of $150.7 million for FY2025, which is 20.42% down from last year.
  • Enanta Pharmaceuticals' Operating Expenses amounted to $33.5 million in Q3 2025, which was down 9.93% from $37.2 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Operating Expenses high stood at $58.1 million for Q4 2021, and its period low was $33.5 million during Q3 2025.
  • Over the past 3 years, Enanta Pharmaceuticals' median Operating Expenses value was $44.5 million (recorded in 2024), while the average stood at $45.7 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 33.65% in 2021, then dropped by 24.63% in 2025.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Operating Expenses stood at $58.1 million in 2021, then dropped by 7.68% to $53.6 million in 2022, then decreased by 1.32% to $52.9 million in 2023, then declined by 23.42% to $40.5 million in 2024, then dropped by 24.63% to $33.5 million in 2025.
  • Its last three reported values are $33.5 million in Q3 2025, $37.2 million for Q2 2025, and $39.5 million during Q1 2025.